The fallout from the Southern California wildfires has one Boston-based nonprofit expediting the services it offers to ...

Having counseled thousands of patients through their breast cancer diagnosis, I was fully aware of how nondiscriminatory this ...

Check out our weekly list of new fundraisers from Lend A Hand Up, a nonprofit crowdfunding site supporting families in Cass, ...

Mentor, mother, activist, advocate, sister, survivor, researcher and Fred Hutch friend, Bridgette Hempstead died last month ...

In addition to using gemcitabine and the natural killer cells that are TGF-β imprinted, we also are combining an anti-GD2 antibody called naxitamab that's provided by Y-mAbs. Naxitamab, as I said, is ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Arvinas (ARVN) announced updated guidance for the planned first- and second-line combination clinical trials for vepdegestrant in patients with ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...